Open AccessConditional disease-free survival in high-risk renal cell carcinoma treated with sunitinib
Author(s) -
Ning Shao,
Hengchuan Su,
Dingwei Ye
Publication year - 2019
Publication title -
aging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.473
H-Index - 90
ISSN - 1945-4589
DOI - 10.18632/aging.102549
Subject(s) - sunitinib , medicine , hazard ratio , clinical endpoint , placebo , renal cell carcinoma , nomogram , oncology , urology , surgery , confidence interval , randomized controlled trial , pathology , alternative medicine
Disease-free survival (DFS) did not reflect accurate individual prognosis after initial diagnosis. As conditional DFS (CDFS) could provide dynamic prognostic information, we evaluated CDFS in these patients treated with or without sunitinib.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom